Exelixis
EXEL
$36.78
Share price
0.82%
Change (1 day)
57.92%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - Total debt
Total debt on the balance sheet as of December 2024 : $0.19 Billion USD
According to Exelixis's latest financial reports the company's total debt is $0.19 Billion USD. A company’s total debt is the sum of all current and non-current debts.
Exelixis - Total debt on balance sheet (from 2000 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | $0.19 B | 0.46% |
| 2023-12-31 | $0.18 B | -0.12% |
| 2022-12-31 | $0.19 B | 270.9% |
| 2021-12-31 | $51.27 M | 4.45% |
| 2020-12-31 | $49.08 M | 2.24% |
| 2019-12-31 | $48.01 M | 221.88% |
| 2018-12-31 | $14.91 M | -0.15% |
| 2017-12-31 | $14.93 M | -92.1% |
| 2016-12-31 | $0.18 B | -54.75% |
| 2015-12-31 | $0.41 B | 17.08% |
| 2014-12-31 | $0.35 B | 2.8% |
| 2013-12-31 | $0.34 B | 3.43% |
| 2012-12-31 | $0.33 B | 84.96% |
| 2011-12-31 | $0.18 B | -12.92% |
| 2010-12-31 | $0.20 B | 161.83% |
| 2009-12-31 | $79.61 M | -32.34% |
| 2008-12-31 | $0.11 B | -3.16% |
| 2007-12-31 | $0.12 B | -0.11% |
| 2006-12-31 | $0.12 B | -18.27% |
| 2005-12-31 | $0.14 B | 1.01% |
| 2004-12-31 | $0.14 B | 32.65% |
| 2003-12-31 | $0.11 B | 50.25% |
| 2002-12-31 | $73.93 M | 51.06% |
| 2001-12-31 | $48.94 M | 227.38% |
| 2000-12-31 | $14.95 M | 12.41% |
| 1999-12-31 | $13.3 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 | $21.31 B | 11,070.51% | 🇬🇧 UK |
 | $18.63 B | 9,664.70% | 🇫🇷 France |
 | $37.11 B | 19,347.87% | 🇺🇸 USA |
 | $51.20 B | 26,731.15% | 🇺🇸 USA |
 | $60.09 B | 31,394.63% | 🇺🇸 USA |
 | $36.63 B | 19,097.90% | 🇺🇸 USA |
 | $63.64 B | 33,254.99% | 🇺🇸 USA |
 | $2.95 M | -98.45% | 🇺🇸 USA |
 | $38.68 M | -79.73% | 🇺🇸 USA |